Viome’s acquisition of Circulate Health pairs precision diagnostics with therapeutic plasma exchange, turning biological data into treatment.
Picture the pitch: a clinic visit where a nurse swaps out your plasma, the way a mechanic swaps out old oil, and sends home biomarkers to prove your biological age dropped afterward. It sounds more like a luxury longevity clinic fantasy than a mainstream medical procedure, but therapeutic plasma exchange (TPE) has been a hospital staple for more than 50 years, used to treat autoimmune and neurological conditions.
What is new is the pitch to healthy, health-anxious consumers, and Viome Life Sciences just made a significant bet that this pitch has legs, acquiring Circulate Health, the company that has spent the past several years building precise, physician-guided TPE protocols outside the hospital setting.
Viome built its reputation on a different kind of promise: sequence a person’s gut microbiome and blood RNA, tell them what is happening at a molecular level, and hand them a precision nutrition plan in response. That model has always had a structural limit, though, which is one shared by most of the diagnostics-heavy corner of health tech. Telling a patient their inflammatory markers are elevated is not the same as fixing them, and diet and supplement interventions can only move certain biomarkers so far, so fast.
“We don’t accept that declining health is inevitable,” said Naveen Jain, Viome’s founder. “The future of medicine isn’t treating disease. It’s making health something you can measure and improve, year after year.”
Circulate gives Viome something it did not have before: a physical intervention, delivered through a nationwide network of more than 200 partner clinics, staffed by Circulate-trained nurses under physician oversight.
The microplastics hook
The timing lines up with a genuinely unsettled area of science. Microplastics have been detected in human blood, placental tissue, and even brain samples in recent years, and while the long-term health consequences remain the subject of active research, public anxiety about environmental toxin exposure has outpaced the science considerably.
A study published in the Journal of Clinical Apheresis in 2026 found that Circulate’s TPE protocol was associated with measurable reductions in circulating microplastic particles among patients with elevated baseline levels. That is a genuinely novel data point, and it is easy to see why it is the headline result Viome is leading with: it gives an amorphous, hard-to-address consumer fear (what is all this plastic doing to me?) a concrete, procedural answer, in a way diet advice never quite could.
Measure, act, remeasure
The more interesting structural story here may not be microplastics at all, but the loop Viome is trying to close. Most consumer health-tech platforms are good at the “measure” part and weak on the “act” part, leaving patients with a report full of biomarkers and little clinical infrastructure to change them.
By pairing Viome’s multi-omics diagnostics with Circulate’s clinical delivery network, and folding Circulate co-founder Dr Brad Younggren in as President of the newly formed Viome Pro clinical division, the combined company is positioning itself as something closer to a full-stack longevity platform: diagnose, intervene, then diagnose again to check whether the intervention worked.
Circulate co-founder Dr Eric Verdin, CEO of the Buck Institute, lends the venture some scientific credibility on the aging-research side of that equation.
The number doing the heavy lifting
The claim likely to generate the most attention is a 2025 Aging Cell study reporting an average 2.6-year reduction in biological age across a panel of molecular biomarkers among TPE patients. That figure is exactly the kind of stat built for a wellness headline, though it also raises the harder question the field has struggled with for years: what does a durable reduction in “biological age” predict, and how long does it last without repeat treatment?
This is where Viome’s diagnostic engine becomes more than a marketing accessory. If the company can use its longitudinal RNA and multi-omic data to track individual patients across repeated TPE cycles, rather than relying on single before-and-after snapshots, it has a real shot at building the kind of outcomes evidence that separates a validated intervention from a fashionable one.
Whether “blood filtering” becomes the next Peloton of the wellness-obsessed, or stays a niche procedure for patients under close physician supervision, likely depends less on how good the microplastics number sounds and more on whether repeat, ordinary patients using Viome Pro’s 200-plus clinics see comparable, tracked results over years rather than months.
For now, the acquisition is a clear signal about where consumer longevity medicine thinks it needs to go next: past the report card, and into the clinic chair.
Photograph of Naveen Jain courtesy of Viome
